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Background: The Italian Society of Human Genetics’ (SIGU) recommendations on genetic counseling and
testing for hereditary melanoma state that clinical genetic testing can be offered to Italian melanoma
families with at least two affected members.
Objective: In the framework of a cooperative study, we sought to establish the frequency of cyclin-
dependent kinase inhibitor 2A mutations in melanoma families that underwent clinical genetic counseling
and testing in accordance with the SIGU recommendations at 9 centers in different Italian regions.
Methods: Cyclin-dependent kinase inhibitor 2A testing was conducted by direct sequencing and multiplex
ligation-dependent probe amplification analysis in melanoma families with at least two affected members.
Results: A total of 33% (68/204) of the families harbored cyclin-dependent kinase inhibitor 2A mutations.
In the 145 families with two affected members the mutation frequency was 25%. Three novel mutations,
L94P, A86T, and c.407dupG, were identified among the cases and not in 200 controls.
Limitations: We were unable to perform separate analyses for individual centers, as in some cases the
number of families was too small.
Conclusions: The availability of clinical genetic testing for melanoma to families with just two affected
members in the same branch is justified in Italy in terms of the likelihood of identifying a mutation. ( J Am
Acad Dermatol 2009;61:775-82.)
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776 Bruno et alCyclin-dependent kinase inhibitor 2A (CDKN2A) is
the major high penetrance susceptibility gene iden-
tified to date in melanoma families worldwide.
Mutations in the other known high-risk melanoma
susceptibility gene, cyclin-dependent kinase 4
(CDK4), are very rare.1
CDKN2A codes for two separate tumor suppressor
proteins, p16INK4a and p14ARF, arising from alter-
native first exons (1a and
1b), that are spliced onto the
common exons 2 and 3, but
in different reading frames.
Both proteins act as tumor
suppressors, p16INK4a
through the retinoblastoma
cell cycle control pathway,
and p14ARF through the p53
pathway. Most CDKN2A mu-
tations are missense muta-
tions located in the coding
sequences of exons 1a and 2,
and many seem to derive
from ancestral founders.2-11
CDKN2A mutations have
been found in 20% to 40% of
melanoma families with 3 or
more affected members.1
However, the proportion of
families with mutations
varies between countries, depending on factors
such as baseline melanoma incidence rates and
family and population selection in studies. A recent
collaborative study by 17 research groups belonging
to the International Melanoma Genetics Consortium
(GenoMEL) studied CDKN2A mutations across 385
families with 3 or more confirmed affected mem-
bers,10 at least two of whom underwent mutational
testing. Overall, 39% of the families were CDKN2A
mutation-positive, ranging from 20% in Australia, to
45% in North America, and 57% in Europe. A high
number of patients with melanoma per family, early
age of onset, and the presence of multiple primary
tumors showed significant associations with
CDKN2A mutations, but the effects varied widely
across continents.
In Italy, studies on smaller samplesof families9,11-15
reported that CDKN2A mutations are found in Italian
families with just two cases and in families with larger
numbers of affected members.
Based on this background, we aimed to establish
the frequency of CDKN2A and CDK4 mutations in
melanoma families that underwent clinical genetic
counseling and testing at centers in different Italian
regions in accordance with the Italian Society of
Human Genetics’ (SIGU) recommendations16,17 and,
therefore, to verify to what extent compliance with
those recommendations results in testing of individ-
uals with a reasonable chance of carrying a mutation.
The second aim of this study was to evaluate the
relationship between presence of CDKN2A or CDK4
mutations, number of affectedmembers in the family,
age at first melanoma diagnosis (AAD), and presence
of multiple primary melano-
mas (MPM) in Italian pro-
bands and their families, to
possibly contribute to an up-
date of the SIGU criterion for
candidacy to testing.
We thus report here the
results of the first co-
operative study on Italian
melanoma families that par-
ticipated in clinical genetic
counseling and testing.
METHODS
Melanoma families and
shared counseling
protocol
The study was conducted
on208 Italianmelanoma fam-
ilies that met the SIGU criteria
and underwent clinical ge-
netic counseling and testing.
The participating centers were SanMartino Hospital in
Genoa; Fondazione IRCSSeIstituto Nazionale dei
Tumori and Istituto Europeo di Oncologia in Milan;
Ospedale di Circolo-Universita` dell’Insubria in Varese;
Ospedale Molinette in Turin; Istituto Oncologico
Veneto in Padua; Policlinico Sant’Orsola-Malpighi in
Bologna; Section of Medical Genetics, University of
Florence; and Istituto Tumori in Bari.
Most of the families were referred for genetic coun-
seling by local oncologists or dermatologists; a subset
was referred by clinicians belonging to the Italian
Melanoma Intergroup in Aviano, Pisa, and Naples.
The number of patients with melanoma, AAD for
each patient, and number of patients with MPM in
each family were recorded.
All of the families in the study were seen between
2000 and 2007. The subset of families seen before
2004, when the SIGU recommendations were
drafted, was reassessed to check compliance with
the SIGU criterion for clinical testing.
Written informed consent was obtained from all
participants under ethics committeeeapproved
protocols.
SIGU’s shared eligibility criteria for clinical genetic
counseling and testing, along with a flow chart
CAPSULE SUMMARY
d In Italy, clinical genetic testing for
melanoma is currently offered to families
with at least two affected members.
d We studied 204 Italian melanoma
families that participated in clinical
genetic counseling and testing, and
found that 33% of the families overall,
and 25% of those with just two affected
members, carried mutations in CDKN2A,
the primary melanoma susceptibility
gene.
d Clinical genetic testing for melanoma in
Italian families with just two affected
members is justified in terms of the
likelihood of identifying a CDKN2A
mutation.
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process, are summarized in Fig 1.
Molecular analyses
Samples from Bari, Istituto Europeo di Oncologia
in Milan, Turin, and Varese were sent to Genoa for
testing, whereas families from the remaining centers
were tested locally. The same standard protocol for
testing was followed at all the centers that performed
molecular analyses.
Genomic DNA was extracted from peripheral
blood using standard methods. The CDKN2A coding
region, including splice junctions, the 5’UTR, the
intronic sequence described to contain the IVS2-105
A/G mutation,18 and exon 1b was entirely se-
quenced, as was CDK4 exon 2.
Detailed protocols of polymerase chain reaction
and sequencing techniques have been previously
described.8
Families were also tested for mutations in CDK4
(exon 2). Evaluation of CDK4 was restricted to exon
2 because no causal mutations have been identified
outside of this exon. For mutation-positive families,
the type of CDKN2A (exons 1a, 2, and 3), ARF (exon
1b), or CDK4 (exon 2) mutation was recorded.
Approximately 90% of the families found to be
negative for mutations in CDKN2A and CDK4 by
sequencing underwent multiplex ligation-depen-
dent probe amplification analysis to investigate the
presence of genomic rearrangements. The majority
(70%) were tested in Florence and Padua19; 20%
were tested in Genoa using the SALSA multiplex
ligation-dependent probe amplification P024B 9p21
CDKN2A/2B kit (MRC-Holland, Amsterdam, the
Netherlands) according to the manufacturer’s in-
structions. The remaining 10% was not tested as
DNA was not available or not sufficient.
Statistical analyses
The nonparametric Wilcoxon-Mann-Whitney test
was used to test the hypothesis of no difference in
the distributions of the variables being compared. All
statistical tests were two sided. Two-tailed P values of
less than .05 were considered statistically significant.
Abbreviations used:
AAD: age at first melanoma diagnosis
CDK4: cyclin-dependent kinase 4
CDKN2A: cyclin-dependent kinase inhibitor 2A
GenoMEL: International Melanoma Genetics
Consortium
MPM: multiple primary melanomas
SIGU: Italian Society of Human GeneticsRESULTS
Patients with melanoma
The 208 participating families included 513 pa-
tients with melanoma; 11 of 513 (2%) could not be
confirmed, but two or more were confirmed in all
families.
The median number of patients (both confirmed
and not confirmed) per family was two, ranging from
two to 11.
Mutation rates
Four noncoding CDKN2A variants with unknown
functional significance were detected in as many
families: IVS1137G[C,13 5’UTR -21C[T,20 e56G[T
and IVS2 -2A[G. As the pathogenicity of these
variants is still unclear, these 4 families were not
included in any further calculation.
A total of 33% (68/204) of the families harbored
CDKN2A mutations. A single phenocopy was iden-
tified in a family with two affected members; one of
these patients and an unaffected relative were found
to carry the G23D mutation.11 There was no signif-
icant difference in mutation rate between the families
with one (34/112, 30%) and two (34/92, 37%) (P =
.5744) tested cases. Further analyses were, therefore,
conducted considering the families as a single series.
As shown in Fig 2, 14 different mutations were
found in the 68 mutation-positive families; 50% of the
mutations (n = 7) were observed only once; the
remainder were seen in more than one family. The
most frequent mutations were G101W (in 41 families,
60%), R24P (in 5 families, 7%), P48T (in 5 families,
7%), and E27X (in 4 families, 6%). Thus, although the
G101W founder mutation accounted for roughly
60% of all the mutations identified (41/68 families),
a further 23% is accounted for by other well-
documented (E27X8, G23S9) or potential founder
(P48T21,22) mutations, or recurring mutations
(R24P10).
Three novel mutations, L94P, A86T, and
c.407dupG, were identified among the cases and
not in 200 controls.
No genomic alterations were detected by multi-
plex ligation-dependent probe amplification in the
samples analyzed.
Mutation testing revealed that none of the families
carried mutations in CDK4.
Mutation frequency according to number of
affected cases per family, age at diagnosis, and
presence of multiple primaries
As shown in Fig 3, A, the frequency of mutations
increased significantly with the number of cases
per family. In the 145 families with two affected
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counseling and testing for familial melanoma.members the mutation frequency was 25% (n =
36), in the 41 families with 3 cases it was 46% (n =
19), and it reached 72% (n = 13) in the families
with 4 or more cases. Overall, 54% of the families
with 3 or more cases carried mutations in CDKN2A.
The median AAD was significantly different in
patients from CDKN2A-positive families (42 years,
range 14-78) compared with patients who belongedto families with no mutations (49 years, range 11-93)
(P\ .0001).
Fig 3, B, shows the frequency of CDKN2A muta-
tions in families with MPM cases. The frequency of
mutations increased significantly with the number of
patients with MPM in a family: 24% (34/144) of the
families with no cases of MPM had CDKN2A muta-
tions versus 49% (25/51) of the families with one
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with two or more. Overall, 23% of the mutation-
positive individuals (45 of 198) had developed MPM
versus 9% (26 of 307) of the individuals who did not
carry CDKN2A mutations (P = .0002).
DISCUSSION
There has beenmuchdebatewithinGenoMEL as to
whether clinical genetic testing for familial melanoma
should be implemented. According to GenoMEL’s first
consensus statement23 clinical genetic testing was
premature, although rare exceptions were contem-
plated. In 2002 GenoMEL recognized that in countries
such as Italy, where baseline melanoma incidence
rates are low and founder mutations common, clinical
genetic testing can encourage adherence to clinical
recommendations among mutation carriers.24 Indeed,
Italy was one of the first countries where clinical
genetic testing for familial melanoma was offered in
medical or cancer genetics services. Because at the
time there were no specific recommendations cover-
ing counseling and DNA testing for individuals per-
ceived to be at risk, our clinical protocol was initially
derived from published research and position pa-
pers.16,24-26 In 2004 SIGU drafted its recommenda-
tions,17 whichhave since formed thebasis for access to
genetic counseling and testing in Italy, and constitute
the sharedprotocol adopted by all medical and cancer
genetics services in our country.
In this study we sought to determine the fre-
quency of CDKN2A and CDK4 mutations in mela-
noma families counseled and tested in accordance
with the SIGU recommendations in different Italian
regions, and thus to verify whether compliance with
these recommendations results in testing of individ-
uals with a reasonable chance of carrying a CDKN2A
mutation. The importance of establishing this muta-
tion rate in our country is in the fact that one of the
main reasons why clinical genetic testing for
Fig 2. Cyclin-dependent kinase inhibitor 2A mutation
distribution. Number and frequency of mutation-positive
families are indicated after each mutation name.melanoma has yet to be widely implemented is that
mutation rates in melanoma families vary widely
among countries.27
Because all the participating centers follow the
same, nationally shared protocol, the pool of families
studied was uniformly selected.
As expected, given that very few melanoma
families worldwide have been reported to harbor
mutations in CDK4,28-31 and only one in Italy,15
none of our families harbored mutations in CDK4.
Conversely, 33% of the families overall carried
mutations in CDKN2A. One phenocopy was iden-
tified in a family, but when we compared the
mutation rate of families with one and families
with two tested melanoma cases we found no
significant difference, as expected in a country of
low incidence such as Italy where the likelihood of
chance clustering of cases in a family is low.
Families with two cases accounted for 71%
(145/204) of our entire sample and for 52% (36/68)
of the families that carried CDKN2A mutations; thus
Fig 3. Cyclin-dependent kinase inhibitor 2A mutation
frequency according to number of affected cases (A) and
presence of multiple primary melanomas (MPM ) (B) in
family. CMM, cutaneous malignant melanoma; MUT, mu-
tated; WT, wild-type.
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affected members was 25%. These findings indicate
that if a more conservative criterion for access to
testing were adopted in Italy, such as the presence of
at least 3 patients in the family, a substantial subset of
families with CDKN2A mutations would not be
identified. Indeed, the importance of including the
geographic location in the assessment of candidacy
for genetic counseling was recently stressed in a
review on this topic.32
Interestingly, the mutation rate we observed in the
families with 3 or more melanoma cases (54%) was
similar to the rate seen among the European families
in the GenoMEL study,10 which, however, met a
more stringent selection criterion (presence of at
least 3 affected members).
The G101W founder mutation, the most common
mutation observed to date in families worldwide,10
accounted for approximately 60% of the mutations
detected in our pool of families, and another 23% of
the mutations identified were known as possible
founder mutations, or recurring mutations. Thus,
founder or recurrent mutations seem to underlie
susceptibility in the majority of familial melanoma
cases in Italy, and may explain in part the high
frequency of CDKN2A mutations in our two-case
families.
We detected no genomic rearrangements, con-
firming that these alterations are a rare cause of
melanoma susceptibility.19,33,34
Patients from CDKN2A mutation-positive families
had a significantly younger median AAD compared
with patients who belonged to families with no
mutations (42 vs 49 years, P\ .0001), who in turn
had a significantly earlier AAD compared with the
median age at onset in the general Italian melanoma
population (59 years).35
In general, familial melanoma cases appear to have
an earlier age at diagnosis than nonfamilial cases, and
the incidence of CDKN2A mutations is higher in
families with an early age at onset.13,23,36 In addition,
the first tumor in patients with multiple melanoma
tends to develop earlier than in patients with a single
melanoma.37 The early AAD observed in the CDKN2A
mutation-negative families may be explained by the
impact of other shared predisposing factors and as yet
unknown susceptibility genes. Among our mutation-
positive individuals, 23% had developed MPM versus
9% of those who did not carryCDKN2Amutations (P =
.0002). The frequency of mutations increased signifi-
cantly with the number of patients with MPM in the
family and reached 100% in the families with two or
more MPM, confirming that the number of cases with
MPM increases the likelihood of detecting a germline
CDKN2A mutation in a family.10,37-39In a very recent hospital-based study of single
primary melanoma and MPM,20 we found that the
frequency of CDKN2A mutations in MPM cases was
32.6%. The MPM cases had a 4-fold higher likelihood
of carrying a CDKN2A mutation than the single
primary melanoma cases (odds ratio = 4.27; 95%
confidence interval 2.43-7.53), independent of a
family history of the disease, which suggests that
the SIGU recommendations may be modified in the
future to include the presence of MPM as a criterion
for candidacy to genetic testing.
The main limitation of this study was that we
were unable to conduct separate analyses for each
center to explore possible geographic variations:
indeed, in some cases the number of families was
too small to allow statistical significance.
Furthermore, the ascertainment of families was
not population based, so we cannot rule out that
there may be other families that met the SIGU
criterion for clinical testing and were not analyzed.
However, as testing was conducted on families with
two or more patients with melanomaea broad
criterioneone might infer that the likelihood of a
finding a lower mutation rate if all the families that
met the criterion had been tested is not high.
Overall, our findings confirm that Italian mela-
noma families have a high mutation rate, that many
of these mutation-positive families harbor founder
mutations, and that the availability of clinical testing
for melanoma to families with just two affected
members is justified in our country in terms of the
likelihood of identifying a mutation.
To date, the SIGU recommendations have not
included the presence of pancreatic cancer in the
proband or in first-degree relatives among the crite-
ria for access to genetic counseling for melanoma
susceptibility, given that data on the risk of pancre-
atic cancer in melanoma families are only available
for a single Italian region.8,40 By continuing to study
the families seen at our centers, we expect to be able
to provide nationwide risk estimates.
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